Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

Xiong, Ying; Liu, Li; Yu, Xinbing; Wang, Jiajun; Xi, Wei; Bai, Qi; Qu, Yang; Xu, Jiejie; Guo, Jianming

doi:10.1186/s12885-017-3106-y

Cited by 6 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further assess the utility of SUV39H1 expression as a prognostic factor, we constructed two nomogram models to predict ccRCC patient prognosis by integrating all of the independent prognostic predictors identified by the multivariate analysis 28 . Patients’ OS or RFS probabilities could be predicted from the total score, which was calculated by adding up the points for each parameter (Supporting Information Fig.…”

Section: Resultsmentioning

confidence: 99%

SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis

Wang

Yin

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is a common kidney malignancy characterized by a poor prognosis. Suppressor of variegation 3–9 homolog 1 ( SUV39H1 ), which encodes a histone H3 lysine 9 methyltransferase, has been reported to act as an oncogene in many cancers. However, it is unclear whether SUV39H1 is involved in ccRCC. Here, we report that SUV39H1 expression is frequently upregulated in ccRCC tumors and is significantly correlated with ccRCC progression. SUV39H1 expression level is an independent risk factor for cancer prognosis, and integration with several known prognostic factors predicted ccRCC patient prognosis with improved accuracy than the conventional SSIGN (stage, size, grade and necrosis) prognostic model. Mechanistically, we discovered that siRNA knockdown or pharmacological inhibition of SUV39H1 induced iron accumulation and lipid peroxidation, leading to ferroptosis that disrupted ccRCC cell growth in vitro and in vivo . We also show that SUV39H1 deficiency modulated the H3K9me3 status of the DPP4 (dipeptidyl-peptidase-4) gene promoter, resulting in upregulation of its expression that contributes to ferroptosis. Taken together, our findings provide the mechanistic insight into SUV39H1 -dependent epigenetic control of ccRCC tumor growth and indicate that SUV39H1 may serve as a potential therapeutic target for ccRCC treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis

Wang

Yin

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…In order to use IDH1 as a prognostic factor, two nomograms were constructed to predict prognosis of ccRCC patients, via integrating the independent risk factors from multivariate analysis [ 25 ]. In addition, calibration plots of the nomograms for OS and RFS at 5 and 10 year revealed the good consistency between the actual and predicted survival of patients ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma

2018

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to investigate the role of isocitrate dehydrogenase 1 (IDH1) expression on prognosis of patients with clear cell renal cell carcinoma (ccRCC) following nephrectomy.MethodsWe retrospectively enrolled 358 ccRCC patients undergoing nephrectomy in Renji Hospital. Clinicopathologic features, overall survival (OS) and recurrence-free survival (RFS) of ccRCC patents were all collected. IDH1 expression level was assessed by immunohistochemistry and its association with clinicopathologic features and outcomes were also evaluated. Kaplan-Meier method with the log-rank test was applied to compare survival curves. Multivariate cox regression models were applied to analyze the prognostic value of each factor on OS and RFS of ccRCC patients. Moreover, two nomograms with factors selected by multivariate analysis were constructed to evaluate the prognosis of ccRCC patients, and the calibration plots were built to assess the predictive accuracy of nomograms.ResultsOur data indicated that IDH1 expression level was down-regulated in ccRCC tissues, and it negatively correlated with tumor Fuhrman grade (p = 0.025). Low IDH1 expression was associated with worse OS and RFS for cccRCC patients (OS, p = 0.004; RFS, p = 0.03). In addition, IDH1 could significantly stratify patients’ OS and RFS in intermediate/high risk patients (UISS score ≥ 4) (p = 0.049 and p = 0.004, respectively). Furthermore, incorporating IDH1 with other prognostic factors could predict ccRCC patients’ OS and RFS (OS, c-index = 0.779; RFS, c-index = 0.798) and perform better than TNM and SSIGN system.ConclusionsLow IDH1 expression level might be an adverse prognostic biomarker for clinical outcomes of ccRCC patients, and two nomograms with IDH1 are potential effective prognostic models for ccRCC.

show abstract

“…The ICS score embraced 11 ICS. Myeloid dendritic cells generated chemokine ligand 17 that recruited T cells as well as other activated antigen-presenting cells and was an independent prognostic factor for OS in ccRCC patients [ 25 ]. Tumor-infiltrating neutrophils were involved in the prognostic deterioration of ccRCC by releasing elastase that broke down cell-cell adhesion and promoted tumor propagation [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma

Shi

Niu

Yang

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. Accumulating evidence substantiated that the immune cells were intricately intertwined with the prognosis and therapy of clear cell renal cell carcinoma (ccRCC). We aimed to construct an immune cell signatures (ICS) score model to predict the prognosis of ccRCC patients and furnish guidance for finding appropriate treatment strategies. Methods. Based on The Cancer Genome Atlas (TCGA) database, the normalized enrichment score (NES) of 184 ICSf was calculated using single-sample gene set enrichment analysis (ssGSEA). An ICS score model was generated in light of univariate Cox regression and Least absolute shrinkage and selection operator (Lasso)-Cox regression, which was independently validated in ArrayExpress database. In addition, we appraised the predictive power of the model via Kaplan-Meier (K-M) curves and time-dependent receiver operating characteristic (ROC) curves. Eventually, immune infiltration, genomic alterations and immunotherapy were analyzed between high and low ICS score groups. Results. Initially, we screened 11 ICS with prognostic impact based on 515 ccRCC patients. K-M curves presented that the high ICS score group experienced a poorer prognosis ( P < 0.001 ). In parallel, ROC curves revealed a satisfactory reliability of model to predict individual survival at 1, 3, and 5 years, with area under the curves (AUCs) of 0.744, 0.713, and 0.742, respectively. In addition, we revealed that the high ICS score group was characterized by increased infiltration of immune cells, strengthened BAP1 mutation frequency, and enhanced expression of immune checkpoint genes. Conclusion. The ICS score model has higher predictive power for patients’ prognosis and can instruct ccRCC patients in seeking suitable treatment.

show abstract

Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

Cited by 6 publications

References 30 publications

SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis

SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis

Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma

Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About